Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Assets (2022 - 2025)

Historic Return on Assets for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to 0.57%.

  • InMed Pharmaceuticals' Return on Assets rose 400.0% to 0.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.57%, marking a year-over-year increase of 400.0%. This contributed to the annual value of 0.6% for FY2025, which is 0.0% changed from last year.
  • InMed Pharmaceuticals' Return on Assets amounted to 0.57% in Q3 2025, which was up 400.0% from 0.66% recorded in Q2 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Return on Assets peaked at 0.42% during Q1 2024, and registered a low of 1.4% during Q3 2022.
  • Its 4-year average for Return on Assets is 0.79%, with a median of 0.63% in 2025.
  • In the last 5 years, InMed Pharmaceuticals' Return on Assets soared by 8400bps in 2023 and then tumbled by -5100bps in 2025.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Return on Assets stood at 1.08% in 2022, then soared by 55bps to 0.49% in 2023, then tumbled by -72bps to 0.83% in 2024, then surged by 32bps to 0.57% in 2025.
  • Its Return on Assets stands at 0.57% for Q3 2025, versus 0.66% for Q2 2025 and 0.93% for Q1 2025.